BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625) today announced that the Company’s patented ‘PICM-19’ cells, under development for use in artificial liver support and in-vitro toxicology testing, have significantly outperformed the world’s most widely used human liver cell line in important tests of liver-specific metabolic functions.
